Dendritic cell vaccines in metastasized malignant melanoma

Giornale Italiano di Dermatologia e Venereologia

Volumn 143, Issue 4, 2008, Pages 235-250

  Erdmann, M ^a,b   Schuler Thurner, B ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b NONE   (Germany)

Author keywords

Antigens, neoplasm; Clinical trial; Dendritic cells; Immunotherapy; Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; DENDRITIC CELL VACCINE; FLT3 LIGAND;

ABDOMINAL CRAMP; ALOPECIA; ANOREXIA; APPETITE DISORDER; ARTHRALGIA; ARTHRITIS; ASTHENIA; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL MATURATION; CHEST TIGHTNESS; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DEPRESSION; DIARRHEA; DRUG COST; DRUG SAFETY; DRUG TARGETING; DYSPNEA; EOSINOPHILIA; FATIGUE; FOOT EDEMA; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOGENICITY; IMMUNOMODULATION; INFECTION; LEG CRAMP; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MALAISE; MELANOMA; METASTASIS; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PRURITUS; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 55749112497     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Garbe C and Eigentier TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 2007;17:117-27.
3. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reinigen DS, Cascinelli N et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
4. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40:1825-36.
5. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748-59.
6. Garbelli S, Mantovani S, Palermo B, Giachino C. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? Pigment Cell Res 2005;18:234-42.
7. Satzger I, Schenck F, Kapp A, Gutzmer R. Spontaneous regression of melanoma with distant metastases - report of a patient with brain metastases. Eur J Dermatol 2006;16:454-5.
8. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-32.
9. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dreno B et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008;112:982-94.
10. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7.
11. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206-13.
12. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
13. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002;25:243-51.
14. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
15. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698-703.
16. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001;94:459-73.
17. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003;15:138-47.
18. Scheibenbogen C, Letsch A, Schmittel A, Asemissen AM, Thiel E, Keilholz U. Rational peptide-based tumour vaccine development and T cell monitoring. Semin Cancer Biol 2003;13:423-9.
19. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol Lett 2008;115:33-42.
20. Lutz MB, Kukutsch NA, Menges M, Rossner S, Schuler G. Culture of bone marrow cells in GM-CSF plus high doses of lipopolysaccharide generates exclusively immature dendritic cells which induce alloantigen-specific CD4 T cell anergy in vitro. Eur J Immunol 2000;30:1048-52.
21. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.
22. Steinman RM, Conn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973;137:1142-62.
23. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
24. Witmer-Pack MD, Olivier W, Valinsky J, Schuler G, Steinman RM. Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 1987;166:1484-98.
25. Heufler C, Koch F, Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 1988;167:700-5.
26. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
27. Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 1990;172:631-40.
28. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-302.
29. Chen M, Li YG, Zhang DZ, Wang ZY, Zeng WQ, Shi XF et al. Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. World J Gastroenterol 2005;11:1806-8.
30. Kundu SK, Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 1998;14:551-60.
31. Grigoleit GU, Kapp M, Hebart H, Pick K, Beck R, Jahn G et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. J Infect Dis 2007;196:699-704.
32. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002;2:151-61.
33. Romani N, Graner S, Brang D, Kampgen E, Lenz A, Trockenbacher B et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
34. Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet Cet al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med 1996;184:695-706.
35. Strobl H, Riedl E, Scheinecker C, Bello-Fernandez C, Pickl WF, Rappersberger Ket al. TGF-beta 1 promotes in vitro development of dendritic cells from CD34+ hemopoietic progenitors. J Immunol 1996;157:1499-507.
36. Mackensen A, Krause T, Blum U, Uhrmeister P, Mertelsmann R, Lindemann A. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 1999;48:118-22.
37. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-18.
38. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001;106:271-4.
39. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137-51.
40. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223:1-15.
41. Suen Y, Lee SM, Aono F, Hou S, Loudovaris M, Ofstein G et al. Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC. Cytotherapy 2001;3:365-75.
42. Davis ID, Chen Q, Morris L, Quirk J, Stanley M, Tavarnesi ML et al. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother 2006;29:499-511.
43. Markovic SN, Dietz AB, Greiner CW, Maas ML, Butler GW, Padley DJ et al. Preparing clinical-grade myeloid dendritic cells by electroporation- mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. J Transl Med 2006;4:35.
44. Erdmann M, Dorrie J, Schaft N, Strasser E, Hendelmeier M, Kampgen E et al. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. J Immunother 2007;30:663-74.
45. Bedrosian I, Mick R, Xu S, Nisenbaum H, Paries M, Zhang P et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 2003;21:3826-35.
46. Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000;96:878-84.
47. Davis TA, Hsu FJ, Caspar CB, van Beckhoven A, Czerwinsk DK, Liles TM et al. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. Biol Blood Marrow Transplant 2001;7:517-22.
48. Gajewski TF, Fallarino F, Ashikari A, Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 2001;7:895s-901s.
49. Haenssle HA, Krause SW, Emmert S, Zutt M, Kretschmer L, Schmidberger H et al. Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study. J Immunother 2004;27:147-55.
50. Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transi Med 2004;2:27.
51. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999;104:173-80.
52. Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000;165:3492-6.
53. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001;93:243-51.
54. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C and Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-8.
55. Butterfield LH, Ribas A, Disserte VB, Amarnani SN, Vu HT, Oseguera D et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003;9:998-1008.
56. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 2004;27:354-67.
57. Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001;24:66-78.
58. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26.
59. Chianese-Bullock KA, Woodson EM, Tao H, Boerner SA, Smolkin M, Grosh WW et al. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother 2005;28:412-9.
60. Lotze MT, Shurin M, Esche C, Tahara H, Storkus W, Kirkwood JM et al. Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity. Cancer J Sci Am 2000;6 Suppl 1:S61-6.
61. Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 2000;23:487-98.
62. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
63. Thomas R, Chambers M, Boytar R, Barker K, Cavanagh LL, Mac-Fadyen S et al. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res 1999;9:474-81.
64. Smithers M, O'Connell K, MacFadyen S, Chambers M, Greenwood K, Boyce A et al. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother 2003;52:41-52.
65. Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, DeSilva C et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 2004;53:125-34.
66. Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP et al. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res 2005;11:7692-9.
67. Griffioen M, Borghi M, Schrier PI, Osanto S, Schadendorf D. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. Cancer Immunol Immunother 2004;53:715-22.
68. Dillman R, Selvan S, Schiltz P, Peterson C, Allen K, Depriest C et al. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother Radiopharm 2004;19:658-65.
69. Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, White-side T et al. Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest 2000;29:121-5.
70. Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 2006;55:819-29.
71. Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008;31:101-12.
72. Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res 2003;9:641-9.
73. Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA et al. Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol 2002;138:799-802.
74. Quillien V, Moisan A, Carsin A, Lesimple T, Lefeuvre C, Adamski H et al. Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging 2005;32:731-41.
75. Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarriere N et al. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res 2006;12:7380-8.
76. Grover A, Kim GJ, Lizee G, Tschoi M, Wang G, Wunderlich JR et al. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 2006;12:5801-8.
77. von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, Peguillet I et al. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J Transl Med 2008;6:6.
78. O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003;52:387-95.
79. O'Rourke MG, Johnson MK, Lanagan CM, See JL, O'Connor LE, Slater GJ et al. Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res 2007;17:316-22.
80. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003;9:5091-100.
81. de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005;23:5779-87.
82. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23:1407-13.
83. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
84. Andersen MH, Keikavoussi P, Brocker EB, Schuler-Thurner B, Jonassen M, Sondergaard I et al. Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression. Int J Cancer 2001;94:820-4.
85. Escobar A, Lopez M, Serrano A, Ramirez M, Perez C, Aguirre A et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005;142:555-68.
86. Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa Tet al. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 2003;13:521-30.
87. Ridolfi R, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Ballardini Met al. Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med 2006;4:36.
88. Vilella R, Benitez D, Mila J, Lozano M, Vilana R, Pomes J et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother 2004;53:651-8.
89. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006;13:905-18.
90. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-70.
91. Schuler-Thurner B, Schulte ES, Berger TG, Weinlich G, Ebner S, Woerl P et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002;195:1279-88.
92. Tuettenberg A, Becker C, Huter E, Knop J, Enk AH, Jonuleit H. Induction of strong and persistent Melan A/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int J Cancer 2006;118:2617-27.
93. Nakai N, Asai J, Ueda E, Takenaka H, Katoh N, Kishimoto S. Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells. J Dermatol 2006;33:462-72.
94. Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 2006;29:545-57.
95. Trakatelli M, Toungouz M, Blocklet D, Dodoo Y, Gordower L, Laporte M et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother 2006;55:469-74.
96. Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 2000;86:385-92.
97. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-8.
98. Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. CHn Cancer Res 2004;10:5381-90.
99. Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother 2005;28:505-16.
100. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004;53:275-306.
101. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
102. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995;63:375-80.
103. Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM et al. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother 1998;21:27-31.
104. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996;98:1633-41.
105. Schaft N, Dome J, Thumann P, Beck VE, Muller I, Schultz ES et al Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol 2005;174:3087-97.
106. Kyte JA, Kvalheim G, Aamdal S, Saeboe-Larssen S, Gaudernack G. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther 2005;12:579-91.
107. Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 2000;106:1065-9.
108. de Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003;63:12-7.
109. Eggert AA, Schreurs MW, Boerman CC, Oyen WJ, de Boer AJ, Punt CJ et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999;59:3340-5.
110. Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003;198:1023-34.
111. Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth RJ, Jr. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 2001;61:641-6.
112. Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother 2000;49:152-6.
113. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A et al. A clinical development paradigm for cancer vaccines and related biologies. J Immunother 2007;30:1-15.
114. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
115. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001;98:10290-5.
116. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
117. Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004;27:184-90.
118. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
119. Jin P, Wang E. Polymorphism in clinical immunology - From HLA typing to immunogenetic profiling. J Transl Med 2003;1:8.
120. Sun JC, Bevan MJ. Defective CDS T cell memory following acute infection without CD4 T cell help. Science 2003;300:339-42.
121. Panelli MC, Wang E, Monsurro V, Jin P, Zavaglia K, Smith K et al. Overview of melanoma vaccines and promising approaches. Curr Oncol Rep 2004;6:414-20.
122. Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994;73:1731-7.
123. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 1999;163:6867-75.
124. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologie self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
125. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
126. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6.
127. Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007;120:2723-33.
128. Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008;6:12.
129. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007;110:3192-201.
130. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005;28:582-92.
131. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33.
132. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007;13:5243-8.
133. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004;5:1260-5.